A rebrand for proteasome inhibition in solid tumors via continuous hepatic artery infusion.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41196694.
- Also identified by DOI 10.1172/jci.insight.199200 and PMC identifier 12890499.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeting tumors with proteosome inhibitors has demonstrated antitumor activity and has been successfully translated to the clinic for patients with multiple myeloma. However, in patients with solid tumors, treatment with proteosome inhibitors as single agents has consistently failed to yield meaningful responses. In our study, we investigate the potential of hepatic artery infusion pump delivery of carfilzomib, to continuously direct a large dose to the tumor with least hepatic toxicity.
Medical subject headings
- Proteasome Inhibitors
- Oligopeptides
- Neoplasms
- Antineoplastic Agents